
Galeterone-induced Degradation of the Androgen Receptor Involves Inhibition of Deubiquitinating Enzymes

Abstract

Galeterone is a highly selective oral small molecule drug candidate that disrupts androgen receptor (AR) signaling through degradation of the AR¹, is a potent CYP17 lyase inhibitor^{2,3}, and possesses AR antagonist activity⁴. Galeterone-induced AR degradation was observed in models having either full-length AR or known constitutively active truncated forms of the AR receptor that lack the ligand binding domain (LBD), AR-V7 and AR567es, suggesting the LBD of the AR is not required for galeterone-dependent AR degradation. Further, galeterone-induced AR degradation activity is blocked by co-administration of the proteasome inhibitor MG132¹. Along these lines, galeterone-induced AR degradation can be blocked by selective knock-down of the E3 ligases, Mdm2 and CHIP¹. We utilized a series of biochemical and cell-based in vitro methodologies to further elucidate and characterize additional signaling molecules participating in the proteasomal-dependent mechanism of galeterone-induced AR degradation. We screened a panel of 22 deubiquitinating enzymes (DUBs) in vitro and demonstrated that galeterone selectively inhibited enzymatic activity of two of the DUBs, USP12 and USP46. Separately, we used surface plasmon resonance to demonstrate a dose-dependent direct binding of galeterone to each of USP12 and USP46, alone or when pre-complexed with UAF1. USP12 is a co-activator of the AR, and selective knock-down of this DUB has been shown to increase AR degradation⁶. USP12/USP46 have also been linked to regulation of phosphatases (PHLPPs) through ubiquitination⁷. PHLPPs dephosphorylate AKT, providing an important regulatory mechanism for controlling the PI3K/AKT pathway. It is known that galeterone induces an increase in pAKT and pMdm2, the latter being a substrate of activated AKT. This suggests that inhibition of USP12/USP46 may regulate pAKT levels through enhanced degradation of PHLPPs via increased ubiquitination. These data support a differentiating mechanism of galeterone from other AR targeting agents whereby inhibition of USP12/USP46 leads to enhanced AR degradation.



Golo

Galeterone: Clinical Development Highlights

- Clinically meaningful PSA₅₀ responses observed in mCRPC patients with C-terminal loss
- AR-V7 is the most common form of C-terminal loss, and is a biomarker for primary resistance to currently-approved oral therapies for mCRPC (abiraterone/enzalutamide)⁸
- Well-tolerated safety profile
- Pivotal Phase 3 clinical trial in treatment-naïve, AR-V7+ mCRPC patients ongoing
- Screening eligibility determined using proprietary assay for AR-V7+
- Primary endpoint: superior rPFS vs. enzalutamide




Daniel T. Dransfield, Nivedita Namdev, Douglas B. Jacoby and Karen J. Ferrante

Tokai Pharmaceuticals, 255 State Street, Boston, MA 02109 w

Galeterone: First-in-Class MOA


• Active in CRPC patients AND supporting data in patients with C-terminal loss


Galeterone: Enhances AR Degradation Within the Proteasome



Boston, MA 02109 <u>www.tokaipharma.com</u>


- Galeterone regulates AR levels through modulation of the E3 ligases, Mdm2 and CHIP¹
- DUB USP12 is a novel coactivator of the AR⁶
- DUBs USP12/USP46 regulate the interaction between the AR and the Akt pathway⁷
- We tested the effect of galeterone on a panel of DUBs (USP2 catalytic domain, USP5, USP25, USP7, USP8, UCHL1, UCHL3, USP9x, USP20, USP19, USP28, USP1/UAF1, USP12, USP12/UAF1, USP46, USP46/UAF1, CYLD, UCHL5, Otubain 2, OTUD3 catalytic domain, Cezanne, Yod1, SARS-PLPro, Trabid, AMSH) in a single point (10µM) *in vitro* biochemical assay





Abstract: #1234





Summary

- Galeterone induces proteasomal degradation of AR/AR-V7 by changing the balance between ubiquitination and deubiquitination
- Galeterone binds to and inhibits USP12/USP46, thereby enhancing proteasomal degradation of AR/AR-V7
 Decreases deubiquitination
- Galeterone induces proteasomal degradation of AR/AR-V7 through modulation of the E3 ligases, Mdm2 and CHIP

 Increases ubiquitination
- Neither abiraterone or enzalutamide induced AR degradation or inhibited USP12/USP46 activity

ddransfield@tokaipharma.com AACR April 2016